Mustang Bio Inc (MBIO)

$0.78 -0.12 (-12.97%)
Market Cap 7.04M
Revenue (ttm) 0.00
Net Income (ttm) -15.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 282,000
Avg Vol 85,108
Day's Range N/A - N/A
Shares Out 7.30M
Stochastic %K 8%
Beta 2.10
Analysts Strong Buy
Price Target $8.00

Company Profile

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 201...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 652 4500
Address:
95 Sawyer Road, Suite 110, Waltham, United States
JoeyLat
JoeyLat Feb. 4 at 12:49 AM
$MBIO back again to say how much more of a pos company this is
0 · Reply
BCINU
BCINU Feb. 3 at 4:43 PM
$MBIO Scott Redler a few years ago told everyone to buy this stock. I wonder how much he made shorting after he went on Fox Business and said buy it.
0 · Reply
BCINU
BCINU Feb. 3 at 4:41 PM
$MBIO management is scum
0 · Reply
QuantNut
QuantNut Feb. 3 at 4:41 PM
$MBIO added 2200 shares cuz im cray cray like that.
0 · Reply
SMM82
SMM82 Feb. 3 at 4:37 PM
$MBIO All time low stock price! Like it for a bounce down around $0.40 based on recent dilution and its previous market cap low. Throw in the recent MB-106/Fred Hutch news and this could be trading around $0.20-0.25 in short order…
0 · Reply
Khamas
Khamas Feb. 3 at 4:04 PM
$MBIO really needs to bounce from this area ...... otherwise ......
0 · Reply
bananaspider
bananaspider Feb. 3 at 4:00 PM
$MBIO
1 · Reply
FinSUN
FinSUN Feb. 3 at 3:44 PM
$MBIO
0 · Reply
SMM82
SMM82 Feb. 3 at 3:26 PM
$MBIO there she goes!
1 · Reply
Hello_AI
Hello_AI Feb. 3 at 1:07 AM
$MBIO wish these purchases to to make them a millionaire
1 · Reply
Latest News on MBIO
Dow Dips 1%; Mustang Bio Shares Spike Higher

Jul 7, 2025, 12:30 PM EDT - 7 months ago

Dow Dips 1%; Mustang Bio Shares Spike Higher

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

Jul 7, 2025, 8:30 AM EDT - 7 months ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

Mar 5, 2025, 4:15 PM EST - 11 months ago

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

FBIO

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Feb 27, 2025, 4:05 PM EST - 1 year ago

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 11, 2025, 4:10 PM EST - 1 year ago

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mustang Bio Announces Closing of $8 Million Public Offering

Feb 10, 2025, 8:00 AM EST - 1 year ago

Mustang Bio Announces Closing of $8 Million Public Offering

Mustang Bio Announces Pricing of $8 Million Public Offering

Feb 6, 2025, 7:00 AM EST - 1 year ago

Mustang Bio Announces Pricing of $8 Million Public Offering

Mustang Bio Announces Reverse Stock Split

Jan 14, 2025, 8:00 AM EST - 1 year ago

Mustang Bio Announces Reverse Stock Split

Mustang Bio Receives Positive Listing Determination from Nasdaq

Nov 12, 2024, 8:30 AM EST - 1 year ago

Mustang Bio Receives Positive Listing Determination from Nasdaq

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Nov 7, 2024, 8:30 AM EST - 1 year ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Oct 24, 2024, 2:10 PM EDT - 1 year ago

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

ENVB

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 21, 2024, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2024, 8:00 AM EDT - 1 year ago

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Why are Mustang Bio shares (MBIO) up almost 500%?

Jun 18, 2024, 2:52 AM EDT - 1 year ago

Why are Mustang Bio shares (MBIO) up almost 500%?

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?

Jun 17, 2024, 9:21 AM EDT - 1 year ago

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

Mustang Bio Announces Closing of $4 Million Public Offering

May 2, 2024, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Closing of $4 Million Public Offering

Mustang Bio Announces Pricing of $4 Million Public Offering

Apr 29, 2024, 8:00 PM EDT - 1 year ago

Mustang Bio Announces Pricing of $4 Million Public Offering

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mar 28, 2024, 9:00 AM EDT - 2 years ago

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Mar 11, 2024, 4:05 PM EDT - 2 years ago

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Mar 7, 2024, 7:30 AM EST - 2 years ago

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Jan 11, 2024, 8:30 AM EST - 2 years ago

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Dec 11, 2023, 8:30 AM EST - 2 years ago

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 14, 2023, 4:05 PM EST - 2 years ago

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Nov 2, 2023, 9:28 AM EDT - 2 years ago

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 30, 2023, 2:15 PM EDT - 2 years ago

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 12:30 PM EDT - 2 years ago

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Oct 26, 2023, 9:00 AM EDT - 2 years ago

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

Sep 7, 2023, 8:15 AM EDT - 2 years ago

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Aug 16, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Mustang Bio to Participate in Two August 2023 Investor Conferences

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio to Participate in Two August 2023 Investor Conferences

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

Jul 31, 2023, 8:30 AM EDT - 2 years ago

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

Mustang Bio Announces Participation in Upcoming Scientific Meetings

Jul 6, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Participation in Upcoming Scientific Meetings

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Jun 15, 2023, 4:01 PM EDT - 2 years ago

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

May 18, 2023, 8:03 AM EDT - 2 years ago

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 12, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

May 11, 2023, 4:03 PM EDT - 2 years ago

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Mar 29, 2023, 4:15 PM EDT - 3 years ago

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

Mar 28, 2023, 8:30 AM EDT - 3 years ago

Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

Jan 17, 2023, 8:15 AM EST - 3 years ago

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Dec 19, 2022, 8:30 AM EST - 3 years ago

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Nov 14, 2022, 4:05 PM EST - 3 years ago

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

Oct 27, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Oct 6, 2022, 8:30 AM EDT - 3 years ago

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio: This Horse May Gallop Still

Sep 23, 2022, 4:55 PM EDT - 3 years ago

Mustang Bio: This Horse May Gallop Still

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

JoeyLat
JoeyLat Feb. 4 at 12:49 AM
$MBIO back again to say how much more of a pos company this is
0 · Reply
BCINU
BCINU Feb. 3 at 4:43 PM
$MBIO Scott Redler a few years ago told everyone to buy this stock. I wonder how much he made shorting after he went on Fox Business and said buy it.
0 · Reply
BCINU
BCINU Feb. 3 at 4:41 PM
$MBIO management is scum
0 · Reply
QuantNut
QuantNut Feb. 3 at 4:41 PM
$MBIO added 2200 shares cuz im cray cray like that.
0 · Reply
SMM82
SMM82 Feb. 3 at 4:37 PM
$MBIO All time low stock price! Like it for a bounce down around $0.40 based on recent dilution and its previous market cap low. Throw in the recent MB-106/Fred Hutch news and this could be trading around $0.20-0.25 in short order…
0 · Reply
Khamas
Khamas Feb. 3 at 4:04 PM
$MBIO really needs to bounce from this area ...... otherwise ......
0 · Reply
bananaspider
bananaspider Feb. 3 at 4:00 PM
$MBIO
1 · Reply
FinSUN
FinSUN Feb. 3 at 3:44 PM
$MBIO
0 · Reply
SMM82
SMM82 Feb. 3 at 3:26 PM
$MBIO there she goes!
1 · Reply
Hello_AI
Hello_AI Feb. 3 at 1:07 AM
$MBIO wish these purchases to to make them a millionaire
1 · Reply
QuantNut
QuantNut Feb. 2 at 8:40 PM
$MBIO 🤮🤮🤮🤮 fuck off.
1 · Reply
FinSUN
FinSUN Feb. 2 at 4:51 PM
$MBIO
0 · Reply
justiceforb_85
justiceforb_85 Jan. 28 at 7:06 PM
$MBIO no updates at all from the company.
1 · Reply
WenMoon9
WenMoon9 Jan. 28 at 2:41 PM
$MBIO under $1??
0 · Reply
SMM82
SMM82 Jan. 28 at 2:27 PM
$MBIO Headed back under $1. All time low around $0.89, about time to give that a test. The July run was fun though.
0 · Reply
FinSUN
FinSUN Jan. 28 at 2:25 PM
$MBIO
0 · Reply
Red2Profit
Red2Profit Jan. 28 at 2:15 PM
$MBIO Hold 2.05 and break 2.33 and we start to curl up. Keep on watch
0 · Reply
Red2Profit
Red2Profit Jan. 25 at 12:32 AM
$MBIO Classic Doji on the weekly. Once 2.04 is triggered next trigger is 6.56 then boomskis!
1 · Reply
patchesmcgillicutty
patchesmcgillicutty Jan. 23 at 10:01 PM
$MBIO I'm a buyer at .45
1 · Reply
Khamas
Khamas Jan. 22 at 7:02 PM
$MBIO if we can just cross that 1.15 area
0 · Reply
Vinniesb
Vinniesb Jan. 22 at 4:45 PM
$MBIO
0 · Reply
prasan2015
prasan2015 Jan. 22 at 3:20 PM
$MBIO marching upwards
0 · Reply